Breast Cancer
📧 Sign up to get email alerts when something new happens for Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-21Clinical Trial Update: Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer [Phase 1, Phase 2]
This clinical trial update reports termination of a Phase Ib/II study evaluating LY2780301 in combination with weekly paclitaxel for HER2-po…
-
CLINICAL_TRIALS withdrawal · 2026-04-17Clinical Trial Update: Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating high-dose vitamin D on cancer biomarkers and breast cancer tumors has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-04-16Clinical Trial Update: Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)
A multicenter observational study evaluating a tumor-informed ctDNA MRD assay for molecular surveillance in early breast cancer has been wit…
-
CLINICAL_TRIALS withdrawal · 2026-04-15Clinical Trial Update: Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS) [Phase 1, Phase 2]
A Phase 1/2 trial CALHYS evaluating ribociclib in combination with hormone therapy and hypofractionated radiotherapy for elderly patients wi…
-
CLINICAL_TRIALS withdrawal · 2026-04-13Clinical Trial Update: 3-Dimensional Conformal Radiation Therapy or Internal Radiation Therapy After Breast-Conserving Surgery in Treating Women With Stage I or Stage II Breast Cancer [NA]
A clinical trial evaluating 3D-conformal radiation therapy or internal radiation therapy after breast-conserving surgery for Stage I/II brea…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2026-04-03Clinical Trial Update: Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
The ECOG-ACRIN trial assessing biomarker testing practices for common solid cancers in community oncology settings has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-03-31Clinical Trial Update: Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer [Phase 1, Phase 2]
A Phase Ib/II study of Abemaciclib plus Elacestrant for brain metastases stemming from HR+/HER2- breast cancer was terminated.
-
CLINICAL_TRIALS withdrawal · 2026-03-11Clinical Trial Update: A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer [Phase 1]
A Phase 1 study evaluating intratumoral influenza vaccine administration in patients with breast cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-03-05Clinical Trial Update: IL-1 Inhibition in Early TNBC [Phase 2]
A Phase 2 trial evaluating IL-1 inhibition in early-stage triple-negative breast cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-02-27Clinical Trial Update: Stereotactic Guided Biopsy and Cryoablation [NA]
A breast cancer clinical trial evaluating stereotactic guided biopsy and cryoablation has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-02-24Clinical Trial Update: Patient Recall of Cancer Screening and Diagnosis [NA]
ClinicalTrials.gov shows that the study NCT05014295 sponsored by Case Comprehensive Cancer Center has been withdrawn; it involves breast can…
-
CLINICAL_TRIALS withdrawal · 2026-02-12Clinical Trial Update: A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer [Phase 3]
Phase 3 trial comparing trastuzumab deruxtecan to CDK4/6 inhibitors in non-luminal A, ER-positive/HER2-low metastatic breast cancer has been…
-
CLINICAL_TRIALS withdrawal · 2026-02-11Clinical Trial Update: Development, Implementation and Evaluation of an Individual Decision Aid in Swedish Cancer Screening Programs [NA]
A clinical trial evaluating an individual decision aid for colorectal, breast, and ovarian cancer screening in Sweden has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-02-06Clinical Trial Update: Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging [Phase 1, Phase 2]
Clinical trial NCT04273555 evaluating early response to a targeted therapy in stage IV HER2-positive breast cancer using advanced PET/MR ima…
-
CLINICAL_TRIALS withdrawal · 2026-02-04Clinical Trial Update: Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer [NA]
Withdrawn clinical trial evaluating a virtual mental health intervention for fear of progression in women with high-risk or stage III-IV gyn…
-
CLINICAL_TRIALS withdrawal · 2025-12-24Clinical Trial Update: Effect of Capivasertib on ctDNA in ER Positive Breast Cancer [Phase 2]
A Phase 2 trial evaluating capivasertib on circulating tumor DNA in estrogen receptor-positive breast cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-12-18Clinical Trial Update: Prospective Comparison of Single-Injection Serratus Anterior Plane Block With Ropivacaine Versus Local Infiltration of Anaesthetic After Breast Surgery [Phase 4]
A Phase 4 trial comparing serratus anterior plane block with ropivacaine versus local anesthetic infiltration for breast cancer surgery was …
-
CLINICAL_TRIALS withdrawal · 2025-12-02Clinical Trial Update: A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer [Phase 1]
Phase 1 trial evaluating BioTTT001, a recombinant human nsIL12 oncolytic adenovirus injection, in combination with neoadjuvant therapy for l…
-
CLINICAL_TRIALS withdrawal · 2025-11-28Clinical Trial Update: (VELA) Study of BLU-222 in Advanced Solid Tumors [Phase 1]
A Phase 1 study of BLU-222 in advanced solid tumors has been terminated.
-
CLINICAL_TRIALS withdrawal · 2025-11-28Clinical Trial Update: A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer
A real-world study in HR+/HER2- advanced/metastatic breast cancer was withdrawn.
-
EMA withdrawal · 2025-11-27EMA Lapsed: Celdoxome pegylated liposomal (doxorubicin hydrochloride) — Baxter Holding B.V.
EMA notes that the marketing authorization for Celdoxome pegylated liposomal doxorubicin hydrochloride has lapsed, covering breast cancer, o…
-
CLINICAL_TRIALS withdrawal · 2025-11-26Clinical Trial Update: The Impact of Intraoperative Methadone on Postoperative Opioid Use [Phase 3]
A Phase 3 trial evaluating intraoperative methadone to reduce postoperative opioid use in breast cancer patients has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-11-18Clinical Trial Update: Cervical Motor Control in Long-term Breast Cancer Survivors [NA]
A clinical trial from Universidad de Granada studying cervical motor control in long-term breast cancer survivors has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-10-23Clinical Trial Update: Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer [Phase 1]
A Phase 1 study evaluating the safety and dosimetry of the radiopharmaceutical [18F]GEH121224 in locally advanced or metastatic breast cance…
-
CLINICAL_TRIALS withdrawal · 2025-10-14Clinical Trial Update: Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer. [Phase 3]
A Phase 3 trial evaluating EG1206A (EirGenix's pertuzumab) versus EU-sourced Perjeta in HER2-positive hormone receptor-negative early breast…